PRAK-03202: A Triple Antigen Virus-Like Particle Vaccine Candidate against SARS CoV-2

The authors developed PRAK-03202, the world’s first triple antigen virus-like particle vaccine candidate, by cloning and transforming SARS-CoV-2 gene segments into a highly characterized S. cerevisiae-based D-Crypt™ platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice.